Compounded semaglutide prices still trail branded Wegovy in late 2026

The price gap that sustains the compounded semaglutide market has not closed. A tracker that checks prices every Monday logged compounded semaglutide at roughly $178 to $299 a month in its September 14, 2026 review, set against $149 for the starting dose of the oral Wegovy pill and $349 for the Wegovy injection through Novo Nordisk's NovoCare program ^[1].

Two sets of prices

Novo Nordisk's published list price for Wegovy is $1,349 a month, a number the tracker says almost no cash-paying patient actually pays. NovoCare, the company's direct program, sells the tablet at $149 for the 1.5 mg starting dose, $199 at 4 mg, and $299 at both 9 mg and 25 mg, the maintenance strength. The weekly injection is $349, and new patients can get their first two fills of the injection at $199 through December 31, 2026 ^[1].

On the compounded side, the same tracker's program listings show Mochi Health at $178 a month with the same rate at starting and maintenance doses, Found advertising $169 but only with a year paid up front ($289 month to month), Noom Med at $199 to $279 all-in with behavioral coaching, and Strut Health at $149 for the starter dose billed month to month ^[1]. Its comparison table gives a compounded range of $178 to $299 a month, or $2,136 to $3,588 a year, while its written text says compounded semaglutide "starts at $149 a month" — the two statements do not match ^[1]. A separate compounding pharmacy page puts compounded semaglutide at typically $150 to $400 a month, versus $935 to $1,349 for brand-name Ozempic or Wegovy without insurance ^[2].

The enforcement backdrop

The FDA declared the semaglutide shortage resolved in February 2025, removing the legal footing that had allowed pharmacies to compound the drug at scale. Deadlines followed: April 22, 2025 for state-licensed 503A pharmacies and May 22, 2025 for 503B outsourcing facilities to stop producing products that were essentially copies of semaglutide ^[2]. Court injunctions blocked part of the 503B enforcement for a time ^[2].

Enforcement escalated after that. The FDA sent a warning letter to Hims & Hers Health in September 2025 and another to Join Josie on February 20, 2026 ^[2]. In March 2026 the agency issued more than 50 warning letters to telehealth firms and compounding pharmacies in one wave, described as the largest action against GLP-1 compounders in U.S. history; Hims and Ro left the compounded semaglutide business ^[2]. On April 30, 2026, the FDA proposed removing semaglutide and tirzepatide from the 503B Bulk Drug Substances List, with public comments open through June 29, 2026 ^[2].

The proposed ban would not close the 503A route. A state-licensed pharmacy may still compound semaglutide for an individual patient with a documented clinical need, such as a reaction to an inactive ingredient in the approved product or a need for a dose or form that is not sold commercially. Cost alone is not an accepted reason under that standard ^[2].

Safety record

Compounded semaglutide is not FDA-approved and is not reviewed by the agency for safety, effectiveness or quality, and its formulation, including which salt form is used, can differ from the approved drug ^[1]. As of April 30, 2025, the FDA had logged 520 adverse event reports involving compounded semaglutide, a figure drawn only from incidents that were reported ^[2]. A frequently cited problem: patients taking 5 to 20 times their intended dose after confusing units with mg/mL on multi-dose vials ^[2].

Why it matters for patients

For anyone paying cash, the arithmetic favors compounded product on price alone: $178 to $299 a month against $349 for the branded injection, though the $149 starter tablet is competitive with the cheapest compounded programs ^[1]. Supply has tightened through 2025 and 2026 as pharmacies paused or exited, so a listed price may not be available at sign-up ^[1].

Insured patients operate on different numbers. Commercial coverage for obesity typically brings the copay to $25 to $100 a month, but prior authorization is the gate, and first requests are often denied ^[1]. Since July 1, 2026, the Medicare GLP-1 Bridge has set a flat $50 monthly price for qualifying Part D beneficiaries ^[1].

What happens next

Industry analysts expect the FDA to finalize the 503B removal in the third quarter of 2026, which would end large-batch semaglutide compounding at outsourcing facilities ^[2]. Novo Nordisk's $199 introductory injection price expires December 31, 2026, and the Medicare Bridge is set to run through December 31, 2027 ^[1]. Whether compounded prices hold after any final rule has not been reported.